As we previously reported, JAMP sought leave to commence an application against Janssen under the abuse of dominance provisions of the Competition Act (the Act), relating to ustekinumab (Janssen’s ...
In a public decision dated August 8, 2024, Justice Furlanetto of the Federal Court found Boehringer Ingelheim’s Canadian Patent No. 2,591,083 (the 083 patent) valid and infringed by JAMP in an action ...
JAMP Pharma's new head office on Boucherville, Québec. (c) Bénédicte Brocard (CNW Group/Fonds de solidarité FTQ) Boucherville, Quebec – October 25, 2016 — JAMP Pharma, a Boucherville based generic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results